News stories about Mesoblast (NASDAQ:MESO) have been trending somewhat positive recently, Accern Sentiment reports. The research firm scores the sentiment of press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Mesoblast earned a coverage optimism score of 0.01 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 45.756669852205 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
MESO has been the subject of several research analyst reports. Maxim Group set a $14.00 price objective on shares of Mesoblast and gave the stock a “buy” rating in a report on Wednesday, November 15th. Zacks Investment Research lowered shares of Mesoblast from a “buy” rating to a “hold” rating in a report on Wednesday, November 1st. Oppenheimer set a $16.00 target price on shares of Mesoblast and gave the company a “buy” rating in a report on Tuesday, November 14th. Finally, Cantor Fitzgerald set a $20.00 target price on shares of Mesoblast and gave the company a “buy” rating in a report on Tuesday, January 16th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the stock. Mesoblast presently has a consensus rating of “Hold” and an average target price of $13.11.
Mesoblast (MESO) traded down $0.12 during mid-day trading on Tuesday, hitting $4.97. 24,700 shares of the stock traded hands, compared to its average volume of 41,794. Mesoblast has a 1 year low of $4.75 and a 1 year high of $12.50. The stock has a market capitalization of $478.91, a price-to-earnings ratio of -6.37 and a beta of 2.43.
Mesoblast (NASDAQ:MESO) last released its earnings results on Tuesday, November 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.15. Mesoblast had a negative net margin of 2,006.86% and a negative return on equity of 12.04%. equities research analysts anticipate that Mesoblast will post -0.91 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “Mesoblast (NASDAQ:MESO) Given Daily Media Impact Score of 0.01” was first posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.thelincolnianonline.com/2018/02/13/mesoblast-meso-given-daily-media-sentiment-score-of-0-01-updated.html.
Mesoblast Company Profile
Mesoblast Limited is engaged in developing cell-based medicines. The Company has leveraged its technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high, unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.